---
layout: default
title: Clopidogrel
parent: 僅模型預測 (L5)
nav_order: 34
evidence_level: L5
indication_count: 8
---

# Clopidogrel
{: .fs-9 }

證據等級: **L5** | 預測適應症: **8** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Clopidogrel: Drug Repurposing Evaluation — No Predictions Available

## One-Sentence Summary

Clopidogrel (DrugBank ID: DB00758) is a pharmaceutical compound submitted for drug repurposing evaluation in this cycle.
However, the TxGNN model did not generate any predicted new indications, and critical data items — including mechanism of action, original indication, and safety information — are currently unavailable.
This report documents the data gaps and outlines the steps required before a substantive evaluation can proceed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in current dataset |
| Predicted New Indication | No prediction generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction not generated; evaluation cannot proceed |
| Italy Market Status | Not marketed (per current dataset) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

No mechanism of action data is available for this evaluation cycle. The `original_moa` field was not populated, and although the DrugBank query returned one result, the MOA content was not extracted into the Evidence Pack.

Because `predicted_indications` is empty, the TxGNN model did not produce any repurposing candidates for Clopidogrel in this run. Without a target indication, it is not possible to assess mechanistic plausibility or the relationship between original and new uses.

Additionally, the original indications list is empty, which prevents a baseline characterisation of what therapeutic area the drug currently addresses.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Italy Market Information

No regulatory authorizations found in the current dataset. The queried Italy market status returned zero licenses.

> **Note:** The TFDA/AIFA package insert query log shows a successful result (`result_count: 1`), but the contents were not parsed into the Evidence Pack. Italy registration data may exist and should be retrieved in the next data collection cycle.

---

## Safety Considerations

Please refer to the package insert for safety information.

> The package insert query returned a successful result but was not parsed into structured safety fields. Key warnings, contraindications, and drug interaction data remain unavailable.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for Clopidogrel is incomplete at a foundational level — no TxGNN predictions were generated and all drug-level data fields are empty or unpopulated. A repurposing evaluation cannot be meaningfully conducted under these conditions.

**To proceed, the following is needed:**

- **Re-run TxGNN prediction pipeline** for DB00758 to generate `predicted_indications` with scores, clinical trial links, and literature references
- **Extract MOA from DrugBank** — the DrugBank query returned 1 successful result; the mechanism of action should be parsed and populated (Data Gap DG002)
- **Parse package insert for safety data** — the TFDA package insert query returned 1 successful result; key warnings and contraindications should be extracted (Data Gap DG001)
- **Verify Italy/AIFA market status** — Clopidogrel is a widely distributed antiplatelet agent; the current 0-license result likely reflects a data pipeline gap rather than actual market absence
- **Populate original indications** — the `original_indications` field is empty and must be filled before any from/to repurposing framing is possible
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

